semaglutide and cardiovascular outcomes in obesity without diabetes journal club #VisualAbstract: Semaglutide and Cardiovascular Outcomes

How did you get so involved with Wilson disease

This can help improve blood flow and support cardiovascular health

Wegovy was in short supply during much of 2022 because of a manufacturing problem, which fueled the demand for alternatives such as Ozempic and Mounjaro, leading to shortages at times for those drugs, too

The effectiveness of the injection and the IV administration are equal

Week 5-8: Low therapeutic dose (5mg) Weekly dose : 5mg (double from 2.5mg) Why this dose : First therapeutic dose Noticeable appetite suppression Steady weight loss begins Side effects still manageable What to expect : Moderate appetite suppression (40-50%) Consistent 1-2 lb weekly loss Nausea reduces (if present initially) Energy normalizes Total weight loss so far : 6-10 lbs Week 9-12: Medium dose (7.5mg) Weekly dose : 7.5mg Why this dose : Increased effectiveness Strong appetite control Accelerated fat loss Still tolerable for most What to expect : Strong appetite suppression (60-70%) 1.5-2 lbs weekly loss Minimal side effects (body adapted) Improved insulin sensitivity Total weight loss so far : 12-18 lbs Week 13-16: High therapeutic dose (10mg) Weekly dose : 10mg Why this dose : Maintenance dose for many users Maximum appetite suppression Optimal metabolic effects Sustainable long-term What to expect : Very strong appetite control (70-80%) Continued 1-2 lb weekly loss Minimal hunger most days Excellent insulin control Total weight loss so far : 18-26 lbs Week 17-20: Maximum dose (12.5-15mg) Weekly dose : 12.5mg or 15mg (optional) Why this dose : For those who plateau at 10mg Additional 3-5% weight loss Maximum therapeutic effect Not needed by everyone What to expect : Maximum suppression (80-90%) Final 5-10 lbs to goal Very little hunger Excellent metabolic health Total weight loss (20 weeks) : 25-35 lbs average Note : Many people maintain at 10mg